Frank Han

Dr. Frank Han

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in JACC
Verified
Journal Article
Closed access
CBCraig S. Broberg
Craig S. Broberg
ADAlexandra C. van Dissel
Alexandra C. van Dissel
JMJessica Minnier
Jessica Minnier
JAJamil Aboulhosn
Jamil Aboulhosn
RKRobert M. Kauling
Robert M. Kauling
AOAlexander R. Opotowsky
Alexander R. Opotowsky

6 September 2024 in eClinicalMedicine
Verified
Journal Article
Open access
SJSupriya S. Jain
Supriya S. Jain
SASteven A. Anderson
Steven A. Anderson
JSJeremy M. Steele
Jeremy M. Steele
HWHunter C. Wilson
Hunter C. Wilson
JMJuan Carlos Muniz
Juan Carlos Muniz
LGLars Grosse-Wortmann
Lars Grosse-Wortmann
We aimed to study the clinical characteristics, myocardial injury, and longitudinal outcomes of COVID-19 vaccine-associated myocarditis (C-VAM). In this longitudinal retrospective observational cohort multicenter study across 38 hospitals in the United States, 333 patients with C-VAM were compared with 100 patients with multisystem inflammatory syndrome in children (MIS-C). We included patients ≤30 years of age with a clinical diagnosis of acute myocarditis after COVID-19 vaccination based on clinical presentation, abnormal biomarkers and/or cardiovascular imaging findings. Demographics, past medical history, hospital course, biochemistry results, cardiovascular imaging, and follow-up information from April 2021 to November 2022 were collected. The primary outcome was presence of myocardial injury as evidenced by late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging. Patients with C-VAM were predominantly white (67%) adolescent males (91%, 15.7 ± 2.8 years). Their initial clinical course was more likely to be mild (80% vs. 23%, p < 0.001) and cardiac dysfunction was less common (17% vs. 68%, p < 0.0001), compared to MIS-C. In contrast, LGE on CMR was more prevalent in C-VAM (82% vs. 16%, p < 0.001). The probability of LGE was higher in males (OR 3.28 [95% CI: 0.99, 10.6, p = 0.052]), in older patients (>15 years, OR 2.74 [95% CI: 1.28, 5.83, p = 0.009]) and when C-VAM occurred after the first or second dose as compared to the third dose of mRNA vaccine. Mid-term clinical outcomes of C-VAM at a median follow-up of 178 days (IQR 114-285 days) were reassuring. No cardiac deaths or heart transplantations were reported until the time of submission of this report. LGE persisted in 60% of the patients at follow up. Myocardial injury at initial presentation and its persistence at follow up, despite a mild initial course and favorable mid-term clinical outcome, warrants continued clinical surveillance and long-term studies in affected patients with C-VAM. The U.S. Food and Drug Administration.

9 September 2019 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
PDF file
FHFrank Han
Frank Han
JCJennifer Co-Vu
Jennifer Co-Vu
DLDalia Lopez-Colon
Dalia Lopez-Colon
JFJohn Forder
John Forder
MBMark Bleiweis
Mark Bleiweis
ACArun Chandran
Arun Chandran
Planning corrective and palliative surgery for patients who have complex congenital heart disease often relies on the assessment of cardiac anatomy using two-dimensional noninvasive cardiac imaging modalities (echocardiography, cardiac magnetic resonance imaging, and computed tomography scan). Advances in cardiac noninvasive imaging now include the use of three-dimensional (3D) reconstruction tools that produce 3D images and 3D printouts. There is scant evidence available in the literature as to what effect the availability of 3D printouts of complex congenital heart defects has on surgical outcomes. Surgical outcomes of study subjects with a 3D cardiac printout available and their paired control subject without a 3D cardiac printout available were compared. We found a trend toward shorter surgical times in the study group who had the benefit of 3D models, but no statistical significance was found for bypass time, cross-clamp time, total time, length of stay, or respiratory support. These preliminary results support the proposal that 3D modeling be made readily available to congenital cardiac surgery teams, for use in patients with the most complex congenital heart disease.

1 October 2019 in Echocardiography
Verified
Journal Article
Closed access
PDF file
FHFrank Han
Frank Han
SKSara Kiparizoska
Sara Kiparizoska
WCWilliam Campbell
William Campbell
CRCamille Richards
Camille Richards
BKBrian Kogon
Brian Kogon
MMMichael McMullan
Michael McMullan

Verified
Journal Article
Open access
PDF file
Shailendra UpadhyayShailendra Upadhyay
Shailendra Upadhyay
ADAnudeep Dodeja
Anudeep Dodeja
OTOlga Toro-Salazar
Olga Toro-Salazar
WFWhitney Fairchild
Whitney Fairchild
FHFrank Han
Frank Han
As the population of adults with congenital heart disease (ACHD) continues to grow, a significant and often underrecognized complication is the development of cardiorenal syndrome (CRS)—a complex, bidirectional interaction between cardiac and renal dysfunction. While CRS has been extensively studied in acquired heart failure, its manifestations and implications in ACHD remain insufficiently understood. Emerging data suggest that renal dysfunction is highly prevalent in ACHD, with significant associations to adverse outcomes regardless of cardiac lesion type or functional status. This review explores CRS within three key physiologic categories in ACHD: patients with a systemic right ventricle, those with a subpulmonary right ventricle, and those with Fontan circulation. Each subgroup presents unique hemodynamic challenges that affect renal perfusion, filtration pressure, and systemic congestion, contributing to both acute and chronic renal impairment. The utility of renal biomarkers such as albuminuria, cystatin C, and estimated glomerular filtration rate (eGFR) is emphasized, alongside the importance of early detection and multidisciplinary management. Heart failure therapy tailored to congenital anatomy, neurohormonal modulation, and careful volume control remain the cornerstones of treatment, while transplantation strategies must consider the potential for irreversible end-organ damage. Given the profound implications of CRS on quality of life and survival, a comprehensive understanding of its pathophysiology and management in ACHD is critical to optimizing long-term outcomes in this increasingly complex patient population.

1 December 2019 in JACC: Case Reports
Verified
Journal Article
Open access
FHFrank Han
Frank Han
MMMichael McMullan
Michael McMullan
WCWilliam F. Campbell
William F. Campbell
The natural history of tetralogy of Fallot depends on whether a transannular pulmonary valve patch or shunt surgery was necessary in infancy. This case illustrates the feasibility of cardiac rest on extracorporeal membranous oxygenation for a very ill adult with conduit endocarditis who received a right ventricle–to–pulmonary artery valveless conduit for later transcatheter pulmonary valve replacement. (Level of Difficulty: Advanced.)